{
    "clinical_study": {
        "@rank": "92513", 
        "arm_group": [
            {
                "arm_group_label": "IQP-AK-102", 
                "arm_group_type": "Active Comparator", 
                "description": "2 capsules per dose, 3 times daily, 30-60 mins before each main meal with a full glass (250 mL) of water"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "2 capsules per dose, 3 times daily, 30-60 mins before each main meal with a full glass (250 mL) of water"
            }
        ], 
        "brief_summary": {
            "textblock": "The individual ingredients in IQP-AK-102 have been widely used. Backed by data from several\n      studies demonstrating their efficacy, we are conducting this study to look into the efficacy\n      and safety of this novel combination of glucomannan, kappa-carrageenan and xanthan gum, in\n      appetite regulation, aiming to reduce the appetite."
        }, 
        "brief_title": "Safety and Efficacy of IQP-AK-102 in Reducing Appetite", 
        "completion_date": {
            "#text": "March 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Weight Loss", 
            "Appetite Modulation (Focus of Study)"
        ], 
        "condition_browse": {
            "mesh_term": "Weight Loss"
        }, 
        "detailed_description": {
            "textblock": "Not available."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age 18 to 65 years\n\n          -  25\u2264BMI\u226435\n\n          -  Expressed desire for weight loss\n\n          -  Accustomed to 3 main meals/day\n\n          -  Generally in good health\n\n          -  Consistent and stable body weight 3 months prior to study enrolment\n\n          -  Consistent regular physical activity\n\n          -  Commitment to avoid the use of other weight loss products during study\n\n          -  Commitment to adhere to diet and lifestyle recommended for the study\n\n        Exclusion Criteria:\n\n          -  Known sensitivity to the ingredients of the device (glucomannan, kappa- carrageenan\n             and xanthan gum)\n\n          -  Presence of any active gastrointestinal disease\n\n          -  Malabsorption disorders\n\n          -  Pancreatitis\n\n          -  Stenosis in the GI tract\n\n          -  Bariatric surgery\n\n          -  Any other reason deemed suitable for exclusion, per investigator's judgement"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 19, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02041754", 
            "org_study_id": "INQ/009913"
        }, 
        "intervention": [
            {
                "arm_group_label": "IQP-AK-102", 
                "intervention_name": "IQP-AK-102", 
                "intervention_type": "Device"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Device"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "January 21, 2014", 
        "location": {
            "contact": {
                "email": "ubongartz@analyze-realize.com", 
                "last_name": "Udo Bongartz, MD", 
                "phone": "+49 30/4000 8543"
            }, 
            "facility": {
                "address": {
                    "city": "Berlin", 
                    "country": "Germany", 
                    "zip": "10369"
                }, 
                "name": "Udo Bongartz"
            }, 
            "investigator": {
                "last_name": "Udo Bongartz, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "2", 
        "official_title": "Double Blind, Randomized, Placebo-controlled, Monocentric Clinical Investigation to Evaluate Efficacy of IQP-AK-102 on Appetite Reduction in Healthy Overweight and Obese Subjects", 
        "overall_contact": {
            "email": "ubongartz@analyze-realize.com", 
            "last_name": "Udo Bongartz, MD", 
            "phone": "+49 30/4000 8543"
        }, 
        "overall_official": {
            "affiliation": "Analyze & Realize", 
            "last_name": "Udo Bongartz, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Germany: Federal Institute for Drugs and Medical Devices", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "March 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Measured using a visual analogue scale (VAS)", 
            "measure": "Difference of VAS between two study arms measured from time '0 to '240 during baseline visit and the final visit", 
            "safety_issue": "No", 
            "time_frame": "4 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02041754"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Measured in kcal", 
                "measure": "Difference in ad libitum energy intake between the two arms at baseline visit and at final visit", 
                "safety_issue": "No", 
                "time_frame": "4 weeks"
            }, 
            {
                "description": "Measured in kcal", 
                "measure": "Change in \"difference in ad libitum energy intake between two study arms\", from baseline visit to the final visit", 
                "safety_issue": "No", 
                "time_frame": "4 weeks"
            }, 
            {
                "description": "Measured using VAS", 
                "measure": "Difference in subjective appetite sensations (VAS) between baseline and the final visit for the two study arms", 
                "safety_issue": "No", 
                "time_frame": "4 weeks"
            }, 
            {
                "description": "Measured in kg. Subjects wearing underwear and no shoes using calibrated weighing scales (Tanita BC-420 SMA)", 
                "measure": "Difference in the mean change in body weight between the 2 arms, from baseline to the final visit", 
                "safety_issue": "No", 
                "time_frame": "4 weeks"
            }, 
            {
                "description": "Measured in cm. Waist: measured at the level midway between the lateral lower rib margin and the iliac crest Hip: measured as the maximal circumference over the buttocks", 
                "measure": "Changes in waist and hip circumference", 
                "safety_issue": "No", 
                "time_frame": "4 weeks"
            }, 
            {
                "description": "Measured in % and kg using bio-impedence method using validated electronic weighing scales (Tanita BC-420 SMA)", 
                "measure": "Changes in body fat content and fat free mass", 
                "safety_issue": "No", 
                "time_frame": "4 weeks"
            }, 
            {
                "measure": "Subjects global feeling of satiety", 
                "safety_issue": "No", 
                "time_frame": "4 weeks"
            }, 
            {
                "description": "15 questions", 
                "measure": "Food Craving Questionnaire", 
                "safety_issue": "No", 
                "time_frame": "4 weeks"
            }, 
            {
                "measure": "Global evaluation of efficacy by the subjects and investigators", 
                "safety_issue": "No", 
                "time_frame": "4 weeks"
            }, 
            {
                "measure": "Global evaluation of safety by the subjects and investigators", 
                "safety_issue": "Yes", 
                "time_frame": "4 weeks"
            }
        ], 
        "source": "InQpharm Group", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "InQpharm Group", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}